1-4 of 4
Eugen Leo, MD, PhD
Close
Sort by
Journal Articles

Final Results of a Phase 2 Open-Label, Monotherapy Efficacy and Safety Study of Quizartinib (AC220) in Patients ≥ 60 Years of Age with FLT3 ITD Positive or Negative Relapsed/Refractory Acute Myeloid Leukemia

Jorge E. Cortes, MD, Alexander E Perl, MD, Hervé Dombret, MD, Sabine Kayser, Björn Steffen, MD, Philippe Rousselot, MD, PhD, Giovanni Martinelli, MD, PhD, Elihu H. Estey, MD, Alan K Burnett, MD, Guy Gammon, MD, Denise Trone, Eugen Leo, MD, PhD, MBA, Mark J. Levis, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 48.
https://doi.org/10.1182/blood.V120.21.48.48
Published: 2012
Journal Articles

Final Results of a Phase 2 Open-Label, Monotherapy Efficacy and Safety Study of Quizartinib (AC220) in Patients with FLT3-ITD Positive or Negative Relapsed/Refractory Acute Myeloid Leukemia After Second-Line Chemotherapy or Hematopoietic Stem Cell Transplantation

Mark J. Levis, MD, PhD, Alexander E Perl, MD, Hervé Dombret, MD, Hartmut Döhner, MD, Björn Steffen, MD, Philippe Rousselot, MD, PhD, Giovanni Martinelli, MD, PhD, Elihu H. Estey, MD, Alan K Burnett, MD, Guy Gammon, MD, Denise Trone, Eugen Leo, MD, PhD, MBA, Jorge E Cortes, MD
Journal: Blood
Blood (2012) 120 (21): 673.
https://doi.org/10.1182/blood.V120.21.673.673
Published: 2012
Journal Articles

A Phase II Open-Label, Ac220 Monotherapy Efficacy Study In Patients with Refractory/Relapsed Flt3-Itd Positive Acute Myeloid Leukemia: Updated Interim Results

Jorge E. Cortes, Alexander E Perl, MD, Catherine C. Smith, MD, Tibor Kovacsovics, MD, Herve Dombret, Hartmut Dohner, MD, Bjorn Steffen, MD, Arnaud Pigneux, MD, PhD, Philippe Rousselot, MD, PhD, Juergen Krauter, MD, Giovanni Martinelli, MD, Elihu H. Estey, MD, Alan K Burnett, MD, Anthony D. Ho, Norbert Ifrah, Theo de Witt, MD, Robert Corringham, MD, Joyce James, PhD, David Lilienfeld, MD, Eugen Leo, MD, PhD, MBA, Guy Gammon, MD, Mark J. Levis, MD, PhD
Journal: Blood
Blood (2011) 118 (21): 2576.
https://doi.org/10.1182/blood.V118.21.2576.2576
Published: 2011
Journal Articles

Novel, 2 ND Generation Histone Deacetylase (HDAC) Inhibitor JNJ-26481585 Exhibits Potent Antitumor Activity Against Chronic Lymphocytic Leukemia Cells In-Vitro and Ex-Vivo .

Kurt Bommert, PhD, Stefan Knop, MD, Janine Arts, PhD, Peter King, PhD, Martin Page, PhD, Eugen Leo, MD, PhD, Ralf Bargou, MD
Journal: Blood
Blood (2007) 110 (11): 4679.
https://doi.org/10.1182/blood.V110.11.4679.4679
Published: 2007